Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IO102-IO103 |
Synonyms | |
Therapy Description |
IO102-IO103 is a peptide vaccine comprised of long peptides derived from IDO and PD-L1, which may result in activation of IDO and PD-L1 specific T lymphocytes, potentially leading to increased antitumor immune response (Annals of Oncology 31 (2020): S1176). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IO102-IO103 | PD-L1/IDO Peptide Vaccine|IO103/IO102 Peptide Vaccine | IO102-IO103 is a peptide vaccine comprised of long peptides derived from IDO and PD-L1, which may result in activation of IDO and PD-L1 specific T lymphocytes, potentially leading to increased antitumor immune response (Annals of Oncology 31 (2020): S1176). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|